In today’s session Foundation Medicine Inc (FMI) registered an unusually high (230) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the February, 2017 call, expecting serious FMI increase. With 230 contracts traded and 30044 open interest for the Feb, 17 contract, it seems this is a quite bullish bet. The option with symbol: FMI170217C00040000 closed last at: $0.5 or 11.1% up. About 70,649 shares traded hands. Foundation Medicine Inc (NASDAQ:FMI) has risen 38.89% since March 2, 2016 and is uptrending. It has outperformed by 30.63% the S&P500.
Analysts await Foundation Medicine Inc (NASDAQ:FMI) to report earnings on November, 1. They expect $-0.87 EPS, down 45.00% or $0.27 from last year’s $-0.6 per share. After $-0.84 actual EPS reported by Foundation Medicine Inc for the previous quarter, Wall Street now forecasts 3.57% negative EPS growth.
Foundation Medicine Inc (NASDAQ:FMI) Ratings Coverage
Out of 7 analysts covering Foundation Medicine (NASDAQ:FMI), 0 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 0 are positive. $30 is the highest target while $19 is the lowest. The $24.33 average target is 2.96% above today’s ($23.63) stock price. Foundation Medicine has been the topic of 9 analyst reports since July 30, 2015 according to StockzIntelligence Inc. The firm has “Neutral” rating by BTIG Research given on Wednesday, November 4. The stock has “Buy” rating given by BTIG Research on Monday, September 14. The stock has “Market Perform” rating given by Wells Fargo on Wednesday, September 16. JMP Securities downgraded Foundation Medicine Inc (NASDAQ:FMI) on Thursday, July 30 to “Market Perform” rating. The company was maintained on Wednesday, September 21 by UBS.
According to Zacks Investment Research, “Foundation Medicine, Inc. provides molecular information products primarily in the United States. The company offers FoundationOne(TM) a molecular information product for the analysis of routine cancer specimens in a clinical setting. Its molecular information platform generates actionable genomic information about a patient’s individual disease, enabling physicians to optimize treatments in clinical practice, and enabling biopharmaceutical companies to develop targeted oncology therapies. Foundation Medicine, Inc. is based in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 1.77 in 2016 Q2. Its up 0.34, from 1.43 in 2016Q1. The ratio improved, as 10 funds sold all Foundation Medicine Inc shares owned while 16 reduced positions. 4 funds bought stakes while 42 increased positions. They now own 10.32 million shares or 3.75% less from 10.73 million shares in 2016Q1.
Moreover, Amer Int has 0% invested in Foundation Medicine Inc (NASDAQ:FMI) for 7,747 shares. Jackson Park Cap Limited Com has 12,500 shares for 0.32% of their US portfolio. The Indiana-based Old National Retail Bank In has invested 0.01% in Foundation Medicine Inc (NASDAQ:FMI). Murphy Michael R accumulated 1.57M shares or 11.54% of the stock. Ipswich Mgmt Inc accumulated 21,800 shares or 0.2% of the stock. Burt Wealth Advisors owns 384 shares or 0.01% of their US portfolio. Moreover, Millennium Management Ltd Liability Com has 0.01% invested in Foundation Medicine Inc (NASDAQ:FMI) for 256,663 shares. Alphamark Advsrs Ltd Liability Co holds 0.53% of its portfolio in Foundation Medicine Inc (NASDAQ:FMI) for 47,981 shares. Bamco Ny has invested 0% of its portfolio in Foundation Medicine Inc (NASDAQ:FMI). One Trading Limited Partnership last reported 304,651 shares in the company. Moreover, Barclays Public Ltd Com has 0% invested in Foundation Medicine Inc (NASDAQ:FMI) for 19,425 shares. Tiaa Cref Investment Limited Liability Corporation has invested 0% of its portfolio in Foundation Medicine Inc (NASDAQ:FMI). Commerzbank Aktiengesellschaft Fi has 0% invested in the company for 11,399 shares. Credit Suisse Ag owns 21,493 shares or 0% of their US portfolio. Bnp Paribas Arbitrage Sa last reported 0% of its portfolio in the stock.
Foundation Medicine, Inc. is a molecular information company. The company has a market cap of $829.21 million. The Firm sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It currently has negative earnings. The Company’s segment is the business of delivering molecular information about cancer to its customers.
FMI Company Profile
Foundation Medicine, Inc., incorporated on November 12, 2009, is a molecular information company. The Firm sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. The Company’s segment is the business of delivering molecular information about cancer to its customers. The Company’s platform includes various methods and algorithms for analyzing specimens across various types of cancer, and for incorporating that information into clinical care. The Company’s products provide genomic information about each patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. The Company’s flagship clinical molecular information products, FoundationOne for solid tumors, and FoundationOne Heme for blood cancers or hematologic malignancies, including leukemia, lymphoma, myeloma and advanced sarcomas, are genomic profiles designed for use in the routine care of patients with cancer.
More recent Foundation Medicine Inc (NASDAQ:FMI) news were published by: Seekingalpha.com which released: “Foundation Medicine: Excellent Risk/Reward Ratios” on October 04, 2016. Also Businesswire.com published the news titled: “Foundation Medicine Announces First-Ever Public Release of Broad Pediatric …” on February 25, 2016. Businesswire.com‘s news article titled: “Foundation Medicine Announces Commercial Launch of Liquid Biopsy Assay …” with publication date: May 03, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.